Aurinia Pharmaceuticals Inc

7.18-0.1100-1.51%Vol 1.51M1Y Perf -2.80%
Oct 4th, 2023 15:50 DELAYED
BID7.18 ASK7.19
Open7.28 Previous Close7.29
Pre-Market7.26 After-Market-
 -0.03 -0.41%  - -
Target Price
12.19 
Analyst Rating
Moderate Buy 1.75
Potential %
68.95 
Finscreener Ranking
★★★★+     57.54
Insiders Trans % 3/6/12 mo.
-/-43/-85 
Value Ranking
★★★+     53.01
Insiders Value % 3/6/12 mo.
-/-39/-99 
Growth Ranking
★★★+     55.09
Insiders Shares Cnt. % 3/6/12 mo.
-/-35/-98 
Income Ranking
 —    -
Price Range Ratio 52W %
37.20 
Earnings Rating
Strong Buy
Market Cap1.03B 
Earnings Date
2nd Nov 2023
Alpha0.02 Standard Deviation0.31
Beta1.28 

Today's Price Range

7.107.42

52W Range

4.0712.43

5 Year PE Ratio Range

-11.30-6.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.65%
1 Month
-22.94%
3 Months
-27.03%
6 Months
-28.18%
1 Year
-2.80%
3 Years
-48.08%
5 Years
15.71%
10 Years
-

TickerPriceChg.Chg.%
AUPH7.18-0.1100-1.51
AAPL173.551.15000.67
GOOG136.172.86502.15
MSFT319.265.87001.87
XOM111.27-4.5650-3.94
WFC38.870.19500.50
JNJ155.420.08000.05
FB196.640.99000.51
GE108.831.06500.99
JPM143.090.37520.26
Financial StrengthValueIndustryS&P 500US Markets
10.00
11.00
0.02
0.02
-1 442.40
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
96.30
-90.00
-87.50
-11 756.30
-77.78
RevenueValueIndustryS&P 500US Markets
105.60M
0.74
467.55
237.58
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.20-0.0860.00
Q01 2023-0.24-0.1825.00
Q04 2022-0.26-0.1830.77
Q03 2022-0.18-0.0666.67
Q02 2022-0.22-0.25-13.64
Q01 2022-0.26-0.27-3.85
Q04 2021-0.26-0.253.85
Q03 2021-0.31-0.39-25.81
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.1710.53Positive
12/2023 QR-0.1220.00Positive
12/2023 FY-0.5818.31Positive
12/2024 FY-0.2738.64Positive
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.17
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.51M
Shares Outstanding143.42K
Shares Float139.20M
Trades Count11.54K
Dollar Volume10.90M
Avg. Volume2.18M
Avg. Weekly Volume2.44M
Avg. Monthly Volume2.00M
Avg. Quarterly Volume2.11M

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 7.29 per share at the end of the most recent trading day (a -2.02% change compared to the prior day closing price) with a volume of 1.56M shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.

The one-year performance of Aurinia Pharmaceuticals Inc stock is -2.8%, while year-to-date (YTD) performance is 68.75%. AUPH stock has a five-year performance of 15.71%. Its 52-week range is between 4.07 and 12.43, which gives AUPH stock a 52-week price range ratio of 37.20%

Aurinia Pharmaceuticals Inc currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 2.53, a price-to-sale (PS) ratio of 10.13, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -29.11%, a ROC of -31.64% and a ROE of -34.16%. The company’s profit margin is -77.78%, its EBITDA margin is -87.50%, and its revenue ttm is $105.60 Million , which makes it $0.74 revenue per share.

Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Moderate Buy (1.75), with a target price of $12.19, which is +68.95% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 13.55, ATR14 : 0.39, CCI20 : -129.28, Chaikin Money Flow : -0.31, MACD : -0.53, Money Flow Index : 11.02, ROC : -17.53, RSI : 24.41, STOCH (14,3) : 3.50, STOCH RSI : 0.00, UO : 32.29, Williams %R : -96.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George Mclean Milne (Buy at a value of $178 284), Joseph M. Miller (Sold 11 296 shares of value $100 986 ), Matthew Donley (Buy at a value of $93 200), Michael R. Martin (Buy at a value of $154 800), Scott Michael Habig (Buy at a value of $25 075), Stephen P. Robertson (Sold 19 402 shares of value $173 454 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (50.00 %)
4 (50.00 %)
4 (50.00 %)
Moderate Buy
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Hold
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.75
Moderate Buy
1.75
Moderate Buy
1.75

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

CEO: Peter S. Greenleaf

Telephone: +1 250 708-4272

Address: 4464 Markham Street, Victoria V8Z 7X8, BC, CA

Number of employees: 294

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

58%42%

Bearish Bullish

67%33%

 

News

Stocktwits